One of Achillion's several HCV compounds in development is ACH-3102, a potent second generation NS5A inhibitor which Achillion discovered in 2011 and nominated as a clinical candidate that same year. Because of the synergy noted in vitro between NS5A inhibitors and NS3 protease inhibitors, Achillion rapidly advanced ACH-3102 through preclinical development and IND-enabling studies. The Company is currently evaluating ACH-3102 in a Phase 2 clinical trial evaluating 12 weeks of ACH-3102 and ribavirin for the treatment of genotype 1b HCV and expects to report SVR results during April of 2013.
Potency. ACH-3102 has demonstrated excellent potency against HCV RNA replication in all genotypes including genotype 1a and resistant mutations.
Combinability. ACH-3102 is highly effective in combination with other oral compounds being developed for the treatment of HCV, and is highly synergistic in vitro when combined with ACH-2684, a NS3 protease inhibitor, and ribavirin.
Specificity. ACH-3102 is highly specific for inhibition of NS5A protein with no inhibition of human proteins.
Pharmacokinetics. ACH-3102 is anticipated to be dosed once-daily.
Safety. To date ACH-3102 has demonstrated a good safety profile in preclinical studies.